Your browser doesn't support javascript.
loading
The Association between Non-Invasive Ventilation and the Rate of Ventilator-Associated Pneumonia.
Saunders, Hollie; Khadka, Subekshya; Shrestha, Rabi; Balavenkataraman, Arvind; Hochwald, Alexander; Ball, Colleen; Helgeson, Scott A.
Afiliação
  • Saunders H; Department of Pulmonary and Critical Care, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.
  • Khadka S; Department of Pulmonary and Critical Care, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.
  • Shrestha R; Department of Pulmonary and Critical Care, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.
  • Balavenkataraman A; Department of Pulmonary and Critical Care, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.
  • Hochwald A; Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL 32224, USA.
  • Ball C; Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL 32224, USA.
  • Helgeson SA; Department of Pulmonary and Critical Care, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.
Diseases ; 11(4)2023 Oct 27.
Article em En | MEDLINE | ID: mdl-37987262
ABSTRACT
Ventilator-associated pneumonia (VAP) has significant effects on patient outcomes, including prolonging the duration of both mechanical ventilation and stay in the intensive care unit (ICU). The aim of this study was to assess the association between non-invasive ventilation/oxygenation (NIVO) prior to intubation and the rate of subsequent VAP. This was a multicenter retrospective cohort study of adult patients who were admitted to the medical ICU from three tertiary care academic centers in three distinct regions. NIVO was defined as continuous positive airway pressure (CPAP), bilevel positive airway pressure (BiPAP), or high-flow nasal cannula (HFNC) for any duration during the hospitalization prior to intubation. The primary outcome variable was VAP association with NIVO. A total of 17,302 patients were included. VAP developed in 2.6% of the patients (444/17,302), 2.3% (285/12,518) of patients among those who did not have NIVO, 1.6% (30/1879) of patients who had CPAP, 2.5% (17/690) of patients who had HFNC, 8.1% (16/197) of patients who had BiPAP, and 4.8% (96/2018) of patients who had a combination of NIVO types. Compared to those who did not have NIVO, VAP was more likely to develop among those who had BiPAP (adj OR 3.11, 95% CI 1.80-5.37, p < 0.001) or a combination of NIVO types (adj OR 1.91, 95% CI 1.49-2.44, p < 0.001) after adjusting for patient demographics and comorbidities. The use of BiPAP or a combination of NIVO types significantly increases the odds of developing VAP once receiving IMV.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article